Neoadjuvant Chemoradiation Therapy Combined With Immunotherapy for MSS Ultra-low Rectal Cancer

Phase 2

Recruiting

• Conditions: Microsatellite Instability Low; Immunotherapy; Neoadjuvant Chemoradiation Therapy; Rectal Cancer
• Interventions: Other: Control; Drug: xintilimab injection

• Registration Number: NCT05215379
• Lead Sponsor: Changhai Hospital

Brief Summary

At present, there are no relevant studies or reports on the effect of neoadjuvant chemoradiation therapy combined with immunotherapy for MSS ultra-low rectal cancer. Studied in this paper combin neoadjuvant chemoradiation with immune therapy, carry out "Multicenter prospective randomized clinical trial of neoadjuvant chemoradiation therapy combined with immunotherapy for MSS ultra-low rectal cancer" in order to provide a high-level evidence-based medical evidence for ultra-low rectal cancer treatment and improve ultra-low rectal cancer diagnosis and treatment effect.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2022-01-05
• Study First Submitted QC: 2022-01-18
• Study First Posted: 2022-01-31
• Study Start: 2022-10-01
• Status Verified: 2023-07
• Last Update Submitted: 2023-07-13
• Last Update Posted: 2023-07-14
• Primary Completion: 2024-10-01
• Study Completion: 2025-04-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 180

Inclusion Criteria

Ultra low rectal cancer patients evaluated by multidisciplinary team to perform APR

• Patients who have a strong desire to preserve the anus and are willing to accept neoadjuvant treatment
• 18 years old ≤ age ≤ 75 years old, no gender limit;
• Colonoscopy, intracavitary ultrasound and pelvic high-resolution MRI (or enhanced CT) were diagnosed as extremely low rectal cancer within 5 cm from the lower edge of the tumor to the anal edge. The baseline clinical stage is T1-3aN0-1M0, and the size of the tumor <1/2 circle;
• Histopathological diagnosis of rectal adenocarcinoma; tumor biopsy immunohistochemistry showed pMMR, that is, MSH1, MSH2, MSH6 and PMS2 four proteins are positive, or genetic testing suggests MSI-L or MSS.
• The patient has good compliance and can come to the hospital for reexamination as required;
• ECOG physical status score 0-1 points;
• Have not received anti-tumor and immunotherapy before being selected;
• 8. Laboratory inspections must meet the following standards: i. White blood cell count ≥3.5×109/L, absolute neutrophil count ≥1.8×109/L, platelet count ≥100×10^9/L, hemoglobin ≥100g/L; ii. INR≤1.5, and APTT≤1.5 times the upper limit of normal value or partial prothrombin time (PTT)≤1.5 times the upper limit of normal value; iii. Total bilirubin≤1.25 times the upper limit of normal; ALT and AST≤5 times the upper limit of normal; iv. 24h creatinine clearance rate ≥50mL/min or blood creatinine ≤1.5 times the upper limit of normal.
• Voluntarily sign the informed consent form;

Exclusion Criteria

• History of other malignant diseases in the past 5 years;
• Patients with metastases ;
• Patients with intestinal obstruction, intestinal perforation, intestinal bleeding, etc. who need emergency surgery;
• Those who are known to be allergic to capecitabine, oxaliplatin, PD-1 monoclonal antibody and other drugs;
• Patients with poorly differentiated adenocarcinoma, signet ring cell carcinoma, and mucinous adenocarcinoma;
• The patient is accompanied by any unstable systemic diseases, including but not limited to: severe infection, uncontrolled diabetes, hypertension that cannot be controlled by drugs, unstable angina, cerebrovascular accident or transient cerebral ischemia, myocardium Infarction, congestive heart failure, severe arrhythmia requiring medication, liver, kidney or metabolic diseases; diseases that affect the life of the patient.
• The patient's accompanying diseases (such as mental illness, etc.) or conditions (such as alcohol or drug abuse, etc.) will increase the patient's risk of receiving experimental drug treatment or affect the patient's compliance with the trial requirements, or may confuse the research results;
• Within 30 days before screening, the patient has received any other experimental drug treatment or participated in another interventional clinical trial;
• Women who are pregnant or breastfeeding or who intend to become pregnant or breastfeeding during the study period; men or women who are unwilling to take effective contraceptive measures;
• The investigator judges that the patient is not suitable to participate in other situations such as the clinical trial.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
neoadjuvant chemoradiation therapy	Control	neoadjuvant chemoradiation therapy
neoadjuvant chemoradiation therapy +immunotherapy	xintilimab injection	neoadjuvant chemoradiation therapy +immunotherapy

Primary Outcome Measures

Name	Time	Method
The rate of cCR	2 years	Rate of patients who achieve clinical complete response

Secondary Outcome Measures

Name	Time	Method
Disease free survival(DFS)	2 years	DFS was defined as the duration from the date of randomization to the date of the first recurrence (local, distant, or mixed) or death.
quality of life	2 years	The QoL was assessed by EORTC QOL Core Questionnaire.
overall survival(OS)	2 years	OS was calculated from the date of randomization.
The rate of organ preservation	2 years	Rate of patients who achieve organ preservation
pCR rate	2 years	Rate of pCR patients after surgery
The rate of anus preservation	2 years	Rate of patients who achieve anus preservation

Trial Locations

Locations (1)

Department of Colorectal Surgery in Changhai Hospital; 🇨🇳 Shanghai, Shanghai, China